Comparative Pharmacology
Head-to-head clinical analysis: NERATINIB MALEATE versus OFEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NERATINIB MALEATE versus OFEV.
NERATINIB MALEATE vs OFEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible inhibitor of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) tyrosine kinases, leading to inhibition of downstream signaling pathways and tumor cell proliferation.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
240 mg (6 tablets of 40 mg) orally once daily with food, continuously until disease progression or unacceptable toxicity.
150 mg orally twice daily, taken with food.
None Documented
None Documented
Terminal half-life is approximately 7–17 hours (mean 12 hours); this supports twice-daily dosing. Steady-state is achieved within 7 days.
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Primarily fecal (approximately 97% of the administered dose recovered in feces as unchanged drug and metabolites); renal excretion is minimal (approximately 1% of the dose recovered in urine).
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor